Interní Med. 2016; 18(2): 97-99 | DOI: 10.36290/int.2016.023

Linagliptin - diabetes safely controlled from the very start

MUDr.Barbora Doležalová1,2, MUDr.Milan Flekač, Ph.D.3
1 Univerzita Pardubice, Fakulta zdravotnických studií, Katedra klinických oborů

This article presents case reports of two patients with type 2 diabetes in whom the use of linagliptin led to long-term excellent

glycemic control, and offered the patients to maintain an active lifestyle without the risk of hypoglycaemia or drug interactions.

Keywords: linagliptin, type 2 diabetes mellitus, therapeutic strategy

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležalová B, Flekač M. Linagliptin - diabetes safely controlled from the very start. Interní Med. 2016;18(2):97-99. doi: 10.36290/int.2016.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brož J, et al. Mortalita pacientů s diabetes mellitus léčených perorálními antidiabetiky v České republice poklesla během let 2003-2013 a přiblížila se populačnímu průměru. Vnitř Lék 2015; 61(11, Suppl 3): 3514-3520.
    2. Doležal T, Kruntorádová K. Klinické a ekonomické přínosy nových antidiabetik v České republice. Vnitř Lék 2015; 61(11, Suppl 3): 3550-3553.
    3. Prázný M. Účinnost a bezpečnost linagliptinu - význam pro klinickou praxi. Interní Med. 2014; 16(2): 62-66.
    4. Slíva J. Základní farmakologie inhibitorů dipeptidylpeptidázy-4. Farmakoterapie 2015; 11(1): 139-142.
    5. Zinman B, et al. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. Can J Diabetes. 2016; 40(1): 50-57. Go to original source... Go to PubMed...
    6. von Eynatten M, et al. Renal Safety and Outcomes With Linagliptin: Meta-Analysis of Individual Data for 5466 Patients With Type 2 Diabetes. Poster 913, 49th Annual Meeting of the EASD, Barcelona, Spain, 23-27 September, 2013.
    7. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism 2011; 13: 7-18. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.